Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Guidelines | English, Portuguese, Spanish
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based guideline:

                

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

The "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors" continues to set evidence-based standards for clinical molecular testing of non-small cell lung cancers (NSCLC) that effectively guides targeted therapy and treatment.

Project Co-Chairs

Philip T. Cagle, MD, on behalf of CAP
Yasushi Yatabe, MD, PhD, on behalf of IASLC
Neal Lindeman, MD on behalf of AMP

External Endorsement

This guideline was endorsed by the American Society of Clinical Oncology on February 5, 2018.

Powered By